Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
920
Trial Sponsor
Trial Collaborator
Clinical Trial Start Date
2007
0Primary Completion Date
2008
0Study Completion Date
2008
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Biological0
Intervention Name
NP-0150
Interventional Trial Phase
Phase 10
Participating Facility
Official Name
Safety and Pharmacokinetics of Anthrax Immune Globulin Intravenous (Human), NP-015, in Healthy Volunteers0
Last Updated
March 18, 2020
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Quadruple0
Masked Party
Participant0
Outcomes Assessor0
Investigator0
Care Provider0
Study summary
The purpose of the study is to assess the pharmacokinetics of three doses of NP-015 (210, 420 or 840 units TNA) in healthy volunteers. To evaluate the safety of NP-015 based on adverse events and laboratory assessments. To determine the dose proportionality relation of three different doses of NP-015.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
